Related references
Note: Only part of the references are listed.Ki67 Heterogeneity in Estrogen Receptor-Positive Breast Cancers: Which Tumor Type Has the Most Heterogeneity?
Takanori Himuro et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2016)
Tumor Heterogeneity in Breast Cancer
Sunil Badve et al.
ADVANCES IN ANATOMIC PATHOLOGY (2015)
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A. S. Coates et al.
ANNALS OF ONCOLOGY (2015)
Strategies for developing Ki67 as a useful biomarker in breast cancer
Carsten Denkert et al.
BREAST (2015)
The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer
Matthias Christgen et al.
HUMAN PATHOLOGY (2015)
Clinical management of breast cancer heterogeneity
Dimitrios Zardavas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification
Charlotte K. Y. Ng et al.
GENOME BIOLOGY (2015)
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
Gaetano Aurilio et al.
EUROPEAN JOURNAL OF CANCER (2014)
Current breast cancer proliferative markers correlate variably based on decoupled duration of cell cycle phases
Lik Hang Lee et al.
SCIENTIFIC REPORTS (2014)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance
Hyesil Seol et al.
MODERN PATHOLOGY (2012)
How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
Zsuzsanna Varga et al.
PLOS ONE (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
Quinci Romero et al.
BMC CANCER (2011)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens
E. A. Rakha et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial
M Mengel et al.
JOURNAL OF PATHOLOGY (2002)
Correlation between MIB-1 and other proliferation markers -: Clinical implications of the MIB-1 cutoff value
F Spyratos et al.
CANCER (2002)
Share Paper
